Quantum BioPharma rockets as media probe revives spoofing claims
Quantum BioPharma stock surged after a Canadian media investigation renewed scrutiny of its allegations that years of market spoofing depressed its valuation and hindered its MS program. The coverage highlighted Quantum $700 million federal lawsuit. The stock jumped 30% Tuesday and gained another 5% after hours, boosted by interest in its Lucid-MS Phase 1 safety data.